Approfondimenti generali
Neoplasie del polmone, Linee Guida AIOM, 2019. [Apri]
Metastatic Non-Small-Cell Lung Cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2018) 29 (suppl 4): iv192–iv237. [Apri] A service of the U.S. National Institutes of Health [Apri]
Referenze bibliografiche specifiche
Liu S, et al. IMpower 133: Primary PFS, OS and Safety in a PH1/3 Study of 1L Atezolizumab + Carboplatin + Etoposide in Extensive-Stage SCLC. WCLC 2018 Abs. n. PL02.07 [Apri]
Rittmeyer A, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–265. [Apri]
Cortinovis D, et al. Immune-Related Adverse Events (irAEs) in Advanced NSCLC Patients Treated With Atezolizumab: Safety Population Analyses From the Ph III Study OAK. Annals of Oncology (2017) 28 (suppl_5): v460-v496. [Apri]